Therapeutics
Developing Next Generation Therapeutics for Healthy Life
Pipeline
Inflammatory & Immunology Diseases
-
Product(Partners)TargetIndicationRegionDiscoveryPreclinicalINDPH1PH2PH3BLA Filing
- FcRn-Targeted Therapies for Autoimmune Diseases
-
view more
Batoclimab HBM9161
FcRn
Myasthenia Gravis
Greater China Rights Out-Licensed
- Type 2 Pathways for Inflammatory & Immunology Diseases
-
HBM9378
TSLP
Asthma
COPD*
Greater China
Greater China
-
BsAb Programs
TSLP×
UndisclosedInflammatory Diseases
Global
- Pathogenic B Cell Depletion for Autoimmune Diseases
-
HBM7020
BCMA×CD3
Autoimmune Diseases
Ex-China
-
TCE Program
CD19×CD3
Autoimmune Diseases
Global
-
BsAb Program
Undisclosed
Autoimmune Diseases
Global
-
TsAb Program
Undisclosed
Autoimmune Diseases
Global
Oncology/Immuno-Oncology
-
Product(Partners)TargetIndicationRegionDiscoveryPreclinicalINDPH1PH2PH3BLA Filing
- mAb for Next-Gen Immuno-Oncology Therapeutics
-
view more
Porustobart HBM4003
CTLA-4
Melanoma
CRC*
HCC*
NEN*
Global
Global
Global
Global
-
view more
HBM1020
B7H7/HHLA2
Solid Tumors
Global
-
HBM1022
CCR8
Solid Tumors
Global
-
HBM9014
LIFR
Solid Tumors
Global
- Immune Cell Engager for Oncology
-
HBM7022
CLDN18.2×CD3
Solid Tumors
Global Out-License
-
view more
HBM7008
B7H4×4-1BB
Solid Tumors
Global
-
HBM7020
BCMA×CD3
Hematologic Carcinoma
Ex-China
-
HBM9027
PD-L1×CD40
Solid Tumors
Global
-
HBM7004
B7H4×CD3
Solid Tumors
Global
- XDC Platform
-
HBM9033
MSLN ADC
Solid Tumors
Global Out-License
-
ADC Program
Undisclosed
Solid Tumors
Global
-
RDC Program
Undisclosed
Solid Tumors
Global
-
PD1 / Chemo
-
Breakthrough Therapy Designation
* CRC = Colorectal Cancer
* HCC = Hepatocellular Carcinoma
* NEN = Neuroendocrine Neoplasm
* COPD = Chronic Obstructive Pulmonary Disease
Publications
-
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial
-
Batoclimab vs placebo for generalized myasthenia gravis: a randomized clinical trial
-
Generation and preclinical evaluation of a human heavy-chain-only antibody recognizing the membrane-bound tumor-associated antigen mesothelin
-
Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models
-
High throughput identification of human monoclonal antibodies and heavy-chain-only antibodies to treat snakebite
-
WNT/beta-catenin signalling interrupts a senescence-induction cascade in human mesenchymal stem cells that restricts their expansion
-
TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China
-
An anti-CTLA-4 heavy chain-only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile
-
A phase I study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma
-
Innovative B7H4 x CD3 & B7H4 x 4-1BB bispecifics for solid tumor therapies
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers
-
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
-
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
-
A human monoclonal antibody blocking SARS-CoV-2 infection
-
SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model
-
Cell Engager Summit Exclusive Speaker Interview
-
Therapeutic response and possible biomarkers in acute attacks of neuromyelitis optica spectrum disorders: a prospective observational study
-
Preclinical evaluation of HBM7022, an HBICE™ 2+1 CLDN18.2 x CD3 bispecific antibody, for gastric cancer
-
Development of fully human T-cell engaging bispecific antibodies targeting B7H4
-
Discovery of potent and functional human antibodies against a new B7-family member, B7H7, for cancer immunotherapy
-
Multimeric single-domain antibody complexes protect against bunyavirus infections
-
HCAb based bispecific immune cell engager (HBICE) platform enables fast and convenient generation of the next generation bispecific antibodies with high potency, promising safety profiles and excellent developability
-
HBM1022, a novel anti-CCR8 antibody, depletes tumor-infiltrating regulatory T cells via enhanced ADCC activity, mediates potent anti-tumor activity
-
Novel monoclonal antibodies (mAbs) targeting human CCR8 provide potential candidates for next generation cancer immunotherapy
-
HBM1007 – A highly potent anti-CD73 mAb candidate for mono and combination IO therapy
-
BCMA x CD3 bispecific antibody – a novel HBICE™-based molecule with efficient tumor killing and minimal cytokine release
-
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
-
A new generation of fully human anti-CTLA-4 heavy chain only antibody
-
A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1